Podcasts about life sciences

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Bayer is reshaping its pharmaceutical business with a new operating model designed to enhance collaboration and bring research & development and commercialization closer together. In a recent episode of The Top Line podcast, Bayer executives Christine Roth, Executive Vice President and Head of Global Product Strategy and Commercialization, and Dr. Yesmean Wahdan, Head of Medical Affairs for the United States and North America, discussed how the company’s Dynamic Shared Ownership framework is driving faster innovation and helping accelerate the development of new therapies for patients. The model removes traditional hierarchies, empowers cross-functional teams and encourages real-time collaboration across departments. Roth and Wahdan said the approach has already shortened regulatory timelines, reduced resource use and helped deliver treatments to patients sooner. By embedding commercial insights early in the research process, Bayer teams can anticipate market needs and focus on the greatest areas of unmet medical demand. The leaders said the company’s collaborative culture keeps patient benefit at the center of decision-making. To learn more about how Bayer’s model is transforming its pipeline, listen to the full episode of The Top Line. See more from Bayer’s Christine Roth and Dr. Yesmean Wahdan on their LinkedIn profiles below: Christine: https://www.linkedin.com/in/christine-roth-34b07b18/ Yesmean: https://www.linkedin.com/in/yesmean-h-wahdan-md-71409b199/ See omnystudio.com/listener for privacy information.

In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.

As AI promises to accelerate drug development, a critical question emerges: can pharmaceutical manufacturing keep pace? In this episode, Martin Wood and Adrian La Porta examine how artificial intelligence could transform the entire pharmaceutical value chain, from quality control paradigms to facility design.Recorded as a preview to Bryden Wood's Accelerate Pharmaceuticals event on 25th November, the discussion explores fundamental questions about the future of drug manufacturing. Adrian argues that current quality systems are essentially compensations for our limited understanding of manufacturing processes - and that AI could enable a complete reversal of this paradigm through real-time, data-driven quality monitoring.The conversation ranges from the potential for patient data feedback loops that could reshape manufacturing in near real-time, to whether facilities should be designed around autonomous systems rather than people. They examine why continuous manufacturing has struggled to gain traction, whether digital twins could eliminate traditional scale-up challenges, and how distributed manufacturing models might reshape global supply chains.A thought-provoking exploration of whether AI can finally bridge the longstanding gap between drug development innovation and manufacturing industrialisation - and what it will take to get there.Send us a textTo learn more about Bryden Wood's Design to Value philosophy, visit www.brydenwood.com. You can also follow Bryden Wood on LinkedIn.

Nick Galakatos, Senior Managing Director, & Global Head of Life Sciences at Blackstone joins Daniel Cassidy at the UBS podcast studio in New York for a comprehensive discussion on trends and developments within Life Sciences, including a look at funding innovations, the regulatory landscape, and the investment case for Life Sciences.

Send us a textIn this episode, an experienced angel investor explains how she evaluates founders, the value of firsthand problem knowledge, and why the best investments balance limited downside with exponential upside.Learn her million-dollar lesson: success comes from focusing on asymmetry, people, and time.https://familyoffices.com/

In this episode of EisnerAmper's Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, speaks with Tadd Wessel, Managing Partner, Petrichor Capital, a New York-based investment firm which invests in health care managers and businesses to drive scientific and medical innovation. Tadd, formerly with OrbiMed Advisors and Fortress Investment Group, shares his outlook for growth capital investing in health care, including the greatest opportunities, challenges and more. ✨ What you'll learn:

Most of us know the story of the Titanic. In 1912, the massive — supposedly indestructible — steamship sank after hitting an iceberg on its first and only journey across the Atlantic Ocean. Titanic remained undiscovered on the seafloor, somewhere in the North Atlantic Ocean, for 73 years, until it was found nearly two miles beneath the surface. But now the ship might be disappearing again, this time for good. And the culprit is not another iceberg — it's something much, much smaller. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Have you ever wondered why your dog takes such a long time to sniff a patch of grass? Or why flies buzz around so sporadically? It’s because most of what a creature actually senses is invisible to us. They perceive their world as differently as we perceive our own. Pulitzer Prize winning science writer Ed Yong wrote a book about this called An Immense World: How Animal Senses Reveal the Hidden Realms Around Us. Join me for a fun conversation with Ed about the astonishing ways animals sense the world around us. From birds that navigate the open ocean by smell, to penguins that sense vibrations underground. By learning how animals perceive their world, it just might change the way we perceive them, and make us look at our own world a little differently. Check out our episode about AI and Animal Communication: Digital Dr. Dolittle: decoding animal conversations with artificial intelligence. Enjoy BONUS CONTENT and help us continue to create this special immersive storytelling by joining THE WILD Patreon community at www.patreon.com/chrismorganwildlife and you can donate to KUOW at kuow.org/donate/thewild. Thank you. Follow us on Instagram @chrismorganwildlife and @thewildpod for more adventures and behind the scenes action! THE WILD is a production of KUOW in Seattle in partnership with Chris Morgan Wildlife and Wildlife Media. It is produced by Matt Martin and Lucy Soucek, and edited by Jim Gates. It is hosted, produced and written by Chris Morgan. Fact checking by Apryle Craig. Our theme music is by Michael Parker.See omnystudio.com/listener for privacy information.

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to another episode of the EUVC Podcast, your trusted inside track on the people, deals, and dynamics shaping European venture.This week, Andreas Munk Holm is joined by Mariette Roesink, Co‑Founder of Curie Capital. Named after Marie Curie, the fund backs breakthrough life science technologies with a mission to both deliver outsized returns and transform patient outcomes.Mariette and her co-founder Han de Groot have already been part of two unicorn exits, raised €200M across their portfolio in a single year, and — most strikingly — can point to zero bankruptcies across 25 investments. As family office-backed GPs, they also invest significant personal capital alongside LPs.They dive into Curie's approach, the unique dynamics of European biotech, why Western Europe is a life science powerhouse, and how to make life science VC anything but “binary.”Whether you're an LP curious about the sector, a GP sharpening your pitch, or a founder in healthtech — this conversation is packed with insights.Here's what's covered:01:00 | Why Curie Capital is named after Marie Curie03:00 | High financial returns + patient impact: the dual promise of biotech05:00 | Why GPs investing their own family money matters07:00 | Raising €200M in “harsh” markets — portfolio highlights09:30 | The billion-dollar impact story of Acerta Pharma12:00 | Building specialist networks & engaging strategics early14:00 | TargED Biotherapeutics: developing a breakthrough stroke therapy17:00 | Zero bankruptcies — besides capital Curie helps theyoung ventures with their network to support raising next roundsand partnering20:00 | The Curie Capital team — science, business, and hands-on support21:30 | Why Western Europe is a life sciences powerhouse23:30 | The 6.1x valuation gap between EU & US early-stage biotech25:00 | The truth about life science holding periods & exits27:00 | Educating LPs: why life science VC isn't as binary as many think

Wilbert Bannenberg is arts, public health consultant en voorzitter van de Stichting Farma ter Verantwoording.***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.

(0:00) Intro(1:55) About the podcast sponsor: The American College of Governance Counsel(2:42) Start of interview(3:56) Sue's origin story(5:42) The Rise of Biotech and her Career Journey (BioRad, Dupont, Amersham and Affymetrix)(12:04) Transition to Venture Capital (Mohr Davidow Ventures, GE Ventures)(14:55) Evolution of Corporate Venture Capital (since ~2010) "They [now] represent about 28% of all VC dollars going into startups."(19:32) Her Board Membership Journey (since 2000, as a board member at Affymetrix where she was an executive)(21:12) The Impact of AI on Governance(21:53) Cultural Differences in Boardrooms between founders and investors: "if you do governance right, it should be an enabler, not a suffocator."(29:24) Navigating Geopolitical Risks. Example: Align Technology: We moved about 90% of our Russia based developers to Armenia.(33:01) Challenges in Life Sciences Funding(34:52) The AI Investment Boom(37:16) Activism's Influence on Corporate Boards. "They punish the lack of communication. They punish obscuring things."  Reference to E189 with Joele Frank and Anne Chapman.(42:36) The Evolution of Compensation Structures "I think one of the key topics around comp is aligning pay, performance, and purpose."(45:34) Other relevant board topics: human capital, innovation, data and board culture.(47:57) The Importance of Board Refreshment (digital and IA natives that can govern in the boardroom)(49:12) Books that have greatly influenced her life:Passages by Gael Sheehy (1976)Mountains Beyond Mountains by Tracy Kidder (2003)(52:00) "People that helped her along"(54:23) An unusual habit or an absurd thing that she loves. (54:59) The living person she most admires: Francis Collins.(56:39) Quotes that she thinks of often or lives her life by.Sue Siegel is a highly accomplished executive, investor, and board member who has been at the forefront of innovation across life sciences, healthcare, and technology for more than three decades. You can follow Evan on social media at:X: @evanepsteinLinkedIn: https://www.linkedin.com/in/epsteinevan/ Substack: https://evanepstein.substack.com/__To support this podcast you can join as a subscriber of the Boardroom Governance Newsletter at https://evanepstein.substack.com/__Music/Soundtrack (found via Free Music Archive): Seeing The Future by Dexter Britain is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License

Gugs Mhlungu chats to Resident CSI & Nature Conservationist, Tim Neary and Lara Fuller, Honorary Research Associate in School of Life Sciences, University of KwaZulu-Natal, about the current state of cranes in South Africa, ongoing efforts to protect their habitats, and the work being done to create a lasting positive impact on their conservation. 702 Weekend Breakfast with Gugs Mhlungu is broadcast on 702, a Johannesburg based talk radio station, on Saturdays and Sundays Gugs Mhlungu gets you ready for the weekend each Saturday and Sunday morning on 702. She is your weekend wake-up companion, with all you need to know for your weekend. The topics Gugs covers range from lifestyle, family, health, and fitness to books, motoring, cooking, culture, and what is happening on the weekend in 702land. Thank you for listening to a podcast from 702 Weekend Breakfast with Gugs Mhlungu. Listen live on Primedia+ on Saturdays and Sundays from 06:00 and 10:00 (SA Time) to Weekend Breakfast with Gugs Mhlungu broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/u3Sf7Zy or find all the catch-up podcasts here https://buff.ly/BIXS7AL Subscribe to the 702 daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 See omnystudio.com/listener for privacy information.

In this episode, Shiv is in conversation with Prasad Chodavarapu, Co-Founder & Managing Director at Aganitha.aiIn this conversation, Prasad, a tech veteran turned bio-pharma enthusiast, discusses his unique career trajectory from software development to founding a startup in the life sciences space. Prasad shares his journey, starting from his early days in tech during the nascent stages of the internet in the mid-90s, working in startups, and his transition to a large enterprise consulting role. The conversation dives into the challenges and learnings from shifting into the bio-pharma industry, the impact of AI in this space, the complexities of scientific data, and the nuances of interdisciplinary collaboration. Prasad also offers valuable career advice for newcomers and those experiencing a mid-career crisis, emphasizing the importance of combining disciplines and lifelong learning. We wrap up with personal insights on how Prasad maintains balance in his life through music and family support.00:00 Introduction and Welcome00:54 Career Beginnings in Software and Technology04:04 Transition to Life Sciences and Biotech07:25 Challenges and Innovations in Scientific Computing09:51 The Role of AI and Data in Modern Science16:29 Preserving and Digitizing Knowledge Systems19:42 Startup Journey and Entrepreneurial Insights24:17 Scientific Collaboration and Practical Applications32:42 Modeling and Prediction Cycles33:37 Validating Predictions in the Lab33:42 Solving Customer Problems with Algorithms35:33 Understanding the Drug Development Value Chain37:41 Challenges in Clinical Trials40:06 The Impact of AI on Science and Technology45:19 Career Advice for Life Sciences and Computing51:18 Personal Techniques for Managing UncertaintyPrasad Chodavarapu is a hands-on tech business exec with 25+ years of exp. in growing tech businesses from start-up stage to a billion-dollar scaleHis expertise and track record is in building multi-disciplinary teamsHe is a published author, with patents in Data and Process engineeringHe is a Co-Founder & Managing Director at Aganitha.aiHis interests include: Deep Science (Comp Bio & Quantum Chem) +  Deep Tech (AI/ML, LLMs, Data, Cloud) for accelerating R&D at global BioPharma, Re-imagining with Agentic & Generative AI, every process & app in disease studies, therapeutic design & dev, synthesis, clinical, medical & regulatory affairs.Among his earlier roles: HCL Tech: SVP & Global delivery head for Transformation ServicesHe is an alumnus of Univ. of Illinois at Urbana-Champaign (UIUC) & IIT KharagpurChannels to reach him:https://www.linkedin.com/in/chprasad/@Omics_Chap on X, @omics-chap.bsky.social on Bluesky

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Europe leads the world in discovery — yet too often, its breakthroughs never become global companies.Billions in research funding turn into patents, not products.While others build empires from ideas, Europe risks becoming the world's laboratory — brilliant, but broke.That's the paradox at the heart of this conversation.In this episode, Karl Nehammer, Vice-President of the European Investment Bank (EIB) and former Chancellor of Austria, joins Christian Soschner live at BIO-Europe 2025 to discuss how Europe can turn its world-class science into world-class companies.He shares how leadership forged in crisis can rebuild confidence, competitiveness, and growth — and why every crisis hides an opportunity to start thinking differently.

As we approach episode 100 of Tiny Matters, we wanted to talk about how it all got started nearly 4 years ago and where we are headed! How did Sam and Deboki become co-hosts? What have they learned about the types of stories and episodes they are drawn to? What happens if an interview goes poorly? What is the American Chemical Society (ACS)? How about Multitude? Will we get 100 MORE episodes of the show? And more... See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode 472 features Dr. Sheila Gujrathi, a biotech entrepreneur, executive, and champion for under represented leaders. Her new book, "The Mirror Effect: A Transformative Approach To Growth For The Next Generation Of Female Leaders" is out now.Chapters:00:00 Introduction and Book Announcement02:15 The Unmet Need: Writing for My Younger Self05:30 Overcoming Challenges: A Personal Journey09:45 The Power of Mentorship and Sponsorship14:00 Spiritual Growth and Finding Purpose18:20 Building a Personal Board of Directors23:10 The Inner Critic and Self-Compassion28:45 The Importance of Storytelling in Leadership33:00 Navigating Negative Work Environments37:15 Conclusion: Embracing Vulnerability and ConnectionFind Sheila Online:Website: ​​https://sheilagujrathimd.com/ TEDxTalk: https://www.youtube.com/watch?v=2DpDx6T3-X4 LinkedIn: https://www.linkedin.com/in/sheila-gujrathi-md/ Instagram: https://www.instagram.com/sheilagujrathimd/ Book: https://sheilagujrathimd.com/book/ About Sheila:Sheila is a biotech entrepreneur, executive, and champion for under represented leaders. Over the past 25 years, she's had the privilege of developing life-changing medicines for patients with serious diseases while building and running private and public biotech companies—including some exciting exits. Today she's a founder, chairwoman, board director, strategic advisor, and consultant to start-up companies and investment funds. Dr. Gujrathi was the co-founder and former CEO of Gossamer Bio and former Chief Medical Officer of Receptos. Her journey started at Northwestern University, where she earned both her M.D. and biomedical engineering degree, and took her from the halls of Harvard, UCSF, and Stanford to the corporate offices of Fortune 500 companies like McKinsey, Genentech, and Bristol-Myers Squibb.Dr. Gujrathi has earned multiple leadership awards, including AIMBE Fellow, BLOC100 Luminary, Healthcare Technology Report Top 25 Women Leaders in Biotechnology, Corporate Directors Forum Director of the Year, and Fiercest Women in Life Sciences. But what really lights her up is creating the inclusive environments she wished she'd had throughout her career. That's why she co-founded the Biotech CEO Sisterhood, a group of trailblazing female CEOs—because we're all better when we support each other.

In this episode, join Michael Sullivan, Senior Vice President, Product Supply Chain NA, Bayer and James Hoskins, Vice President, Operations, Life Sciences and Healthcare, DHL Supply Chain, as they explore our 25-year partnership, organizational strategy and successful collaborations. 

In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today's CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem. Brian shares his perspective on: The outlook for cell and gene therapies, where clinical setbacks, overcapacity, and high costs are balanced by steady innovation and cautious optimism; Why “specialization over scale” is defining the next wave of CDMO success, as niche providers in radiopharma, peptides, and other complex modalities gain traction; and How the evolving Biosecure Act and U.S. reshoring efforts are reshaping global supply chains and creating new opportunities for domestic manufacturing.

Life sciences are staring at a $1.5T revenue hit—time to rethink the playbook. Suppliers can't keep doing what worked yesterday. To help the industry navigate headwinds and continue delivering cures, they'll need new capabilities, new partnerships, and faster execution. In this episode of HFS Unfiltered Stories, Rohan Kulkarni, Executive Research Leader at HFS Research, talks with Paul Watson, Vice President, Global Lead Healthcare & Life Sciences at Hitachi Digital Services, about what it will really take to adapt. They get into:Finding growth in new markets, channels, and engagement modelsRegulatory shifts as more countries run their own approvals (not just the FDA)Speed to value, where partners that can design, build, run, and service plants end-to-end take the leadWatch now for practical insights on where life sciences are headed.Read more: https://www.hfsresearch.com/research/life-sciences-survival-consumers/

The healthcare marketing landscape is evolving fast — shaped by regulatory shifts, patient empowerment, and the rise of digital health marketplaces. In this episode of The Top Line, sponsored by Havas Media Network, host Chris Hayden sits down with Holly Dunn, Managing Partner of Performance at Havas Media Network, to explore how pharma brands can redefine patient engagement for a more connected, equitable future. Dunn explains how first-party data, AI-driven intent signals, and curated health marketplaces are enabling more compliant, transparent, and human-centered campaigns. She also discusses the growing role of healthcare creators, the fight against misinformation, and strategies to ensure high-quality, privacy-safe engagement across the patient journey. If you’re in pharma or biotech marketing, this conversation offers critical insight into how leading brands are building trust and equity in an increasingly complex environment.See omnystudio.com/listener for privacy information.

My guest today is Jeff Skopek, a Professor of Law and the Deputy Director of the Centre for Law, Medicine, and Life Sciences at the University of Cambridge. He holds a J.D. from Harvard Law School and a Ph.D. in the History and Philosophy of Science from the University of Cambridge.His research explores the normative and conceptual foundations of health law, focusing in particular on the health care system, biomedical research, and controversies about what constitutes a harm or benefit within medical care. His recent research also focuses on animal rights. He joins us today to discuss a work in progress, Created To Be Killed.Show NotesAbout Jeff SkopekAbout Kim KrawiecAbout Mason Marché

Hey hey—it's Friday, it's Halloween, and it's time for another round of Stoppage Time with Uncle Rob!In this week's episode, I'm catching up on life, reflecting on Halloween traditions (past and future), and diving deep into the week that was—new Entrepreneurial Thinkers episodes, big developments in California's booming Life Sciences industry, and some personal thoughts on creativity, purpose, and what's next for this very show.You'll hear about my recent conversation with my good friend (and show alum) Dave Whelan as we explore how massive investments and new innovation hubs are shaping the future of Life Sciences in Los Angeles—and how that's changing the way we'll all live and thrive in the years ahead.Beyond that, it's one of those laid-back, honest Fridays where we take a step back and ask: What's this show really about? Has it evolved, or is it ready to evolve again? And how can we make it even more valuable or inspiring for you—our listeners and friends?So grab a coffee (or maybe a little leftover Halloween candy), settle in, and join me for another thoughtful, unscripted hangout full of reflection, inspiration, and a touch of weekend energy.

On the Thursday, Oct. 30 edition of Georgia Today: The parent company of Georgia Power beats Wall Street expectations; Gwinnett County will soon get a new life sciences research park; and frustration builds as the government shutdown continues.

Is our Life Sciences industry the most under-reported unicorn in California's industrial dominance? Can Life Sciences innovation survive the USA government's assault on science? In this eye-opening episode, Rob sits down with friend Dave Whelan, to uncover how LA is rapidly transforming into a major player in biotech and health innovation. They discuss groundbreaking projects like UCLA's new Research Park, the explosion of AI in drug discovery, and how diversity and storytelling are shaping the future of healthcare and life sciences startups. From political roadblocks to billion-dollar opportunities, this conversation is packed with insights for anyone curious about where health tech is heading—and why LA might just be leading the charge.Feel free to follow and engage with DAVE here:LinkedIn: https://www.linkedin.com/in/djwhelan/Instagram: https://www.instagram.com/djwhelanX: https://x.com/djwhelanFacebook: https://www.facebook.com/djwhelanWebsite: https://www.bespokestrategy.com/whelanWe're so grateful to you, our growing audience of entrepreneurs, investors and community leaders interested in the human stories of the Entrepreneurial Thinkers behind entrepreneurial economies worldwide.As always we hope you enjoy each episode and Like, Follow, Subscribe or share with your friends. You can find our shows here, and our new Video Podcast, at “Entrepreneurial Thinkers” channel on YouTube. Plug in, relax and enjoy inspiring, educational and empowering conversations between Rob and our guests.¡Cheers y gracias!,Entrepreneurial Thinkers Team.Chapters00:00 Introduction to Entrepreneurial Thinkers04:46 The Evolution of Life Sciences in California19:03 UCLA Research Park: A New Era for Innovation28:37 The Vision for Life Sciences Development33:31 The Role of Universities in Life Sciences37:23 Navigating Funding Challenges in Academia47:03 Breakthroughs in Life Sciences and AI's Impact56:55 Understanding Neurodegenerative Diseases58:47 Diversity in Innovation and Health Sciences01:06:37 The Importance of Storytelling in Health Tech01:11:56 Dave Whelan's Multifaceted Career and Contributions01:18:04 Key Mistakes in Health Tech Innovation

If you're a female and you want to use a contraceptive pill, patch, injection, or device, you have over 250 options. But if you're a male and you want a contraceptive, you have three options. You can get a vasectomy, you can use condoms, which can have up to a 18% failure rate, or you can use what sex researchers politely call “the withdrawal method,” which is highly unreliable. But there could be another male contraceptive very soon. So what took so long?Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week, Matthew and Lindsay welcome Maynard Nexsen attorney James Childs, who leads the firm's private markets and private equity practice as well as the venture capital and emerging growth practice. In one of our most content-rich episodes to date, James offers a comprehensive look at the legal foundations every life sciences startup needs to understand, from formation to funding. With decades of firsthand experience, James breaks down critical topics including entity structure, intellectual property protection, securities law compliance, investor negotiations, and university licensing. Whether you're launching a biotech startup or preparing for a capital raise, this episode is packed with insights for long-term success. Listen now!

As we near the end of 2025, the CDMO industry finds itself at a pivotal financial and strategic juncture — shaped by constrained funding, shifting demand, and renewed investor scrutiny.  In this episode of Off Script, we speak with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, to examine how the year's market and investment trends align with his predictions from an earlier CPHI Annual Report. Brian shares his perspective on: How accurately his forecast of stability and growth for clinical CROs and CDMOs has held up amid tighter capital markets; The ongoing softness among early-stage pharma service providers and what it reveals about funding flows across the sector; and Where investor interest is gravitating — from ADCs and small molecules to biologics — and what this signals for the next phase of CDMO evolution.

Join AFS Life Sciences Partner Stephanie Trunk and Darshan Kulkarni, Life Sciences regulatory and compliance attorney, to unpack the recent acceleration of mergers and acquisitions across the life sciences sector. They examine why deal flow is increasing, why buyers are favoring asset purchases over mega-deals, and how drug pricing and compliance priorities under the Trump Administration are shaping decisions. They also explore how rigorous due diligence can mitigate risk, where artificial intelligence (AI) may streamline diligence, and why intellectual property (IP) mapping to actual products remains a recurring gap. The discussion closes with practical insights on building a robust compliance culture and navigating an evolving health care enforcement landscape. Key Takeaways Include: - Increasingly, buyers favor strategic, targeted acquisitions over mega-deals. - Policy impacts from the Trump Administration influencing deal strategy. - Heightened due diligence emphasis on compliance and pricing risks. - Emerging role of AI to streamline due diligence workflows. - Persistent gaps in IP diligence, including weak mapping to products.

What happens after we discover life beyond Earth? The question is no longer "if," but "when"—and how humanity responds could shape our future. Host and planetary astronomer Franck Marchis welcomes Martin Dominik, one of the authors of a new white paper on the societal, political, and philosophical challenges we'll face once alien life is confirmed. From public communication and policy to our collective sense of identity, this discussion explores how to prepare for the biggest discovery in human history.

On this special segment of The Full Ratchet, the following Investors are featured: Barry Schuler of DFJ Growth Ventures Shashank Saxena of Sierra Ventures Jeff Bussgang of Flybridge Capital We asked guests to discuss the most visionary founder that they've worked with and what makes them so special. The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area. We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.   Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.

In this episode, hosts Payal Nanavati and Megan Beaver speak with Linda Malek and Matthew F. Ferraro about the latest federal and state developments in artificial intelligence (AI) policy affecting health care. The conversation covers the Trump administration's AI action plan and Executive Orders on AI, new industry-specific and comprehensive state laws, and enforcement trends, with a focus on how these changes impact the health care industry. This podcast episode features the following speakers: Linda Malek is a partner in Crowell & Moring's New York office, and is a member of our Health Care, Privacy & Cybersecurity, and Life Sciences practices. She advises a broad array of health care and life sciences clients on compliance with federal, state, and international law governing clinical research, data privacy, cybersecurity, and fraud and abuse. Linda also counsels digital health and biotech companies developing AI tools. She navigates the complex and evolving federal and state regulatory landscape, balancing the priorities of oversight authorities with issues related to data privacy and security as well as business goals. Matthew F. Ferraro is a partner in Crowell & Moring's Washington, D.C. office and is a member of our Privacy and Cybersecurity Group, where he advises leading organizations on high-impact matters involving artificial intelligence (AI), cybersecurity, and emerging technologies. He previously served as Senior Counselor for Cybersecurity and Emerging Technology to the Secretary of Homeland Security, helping shape national AI and cyber policy and helping to establish and run the Artificial Intelligence Safety and Security Board. Payers, Providers, and Patients – Oh My! is Crowell & Moring's health care podcast, discussing legal and regulatory issues that affect health care entities' in-house counsel, executives, and investors.

Erin Silva, Ph.D. https://cias.wisc.edu/directory/17158/FoA 280: Organic Farming Myths and Realities With Erin SilvaI wanted to invite Erin Silva back on the show to hear about her continued work with farmers that are going down the path of organic AND regenerative. On the surface, those two farming approaches are easy to get behind: let's try to reduce our dependence on synthetic chemistry and let's try to build soil health over time while still farming intensively and profitably. But in practice, there are tradeoffs. To promote more living roots on the soil through cover crops, as one example, farmers need a way to terminate those cover crops and using herbicides for that is really really helpful. So I'm intrigued about how farmers are making these systems work and how scientists like Erin our doing the critical research to understand how these practices can work on more acres for more farmers. So that is what today's episode is all about, and for context I'll give you a brief bio on our guest. Dr. Erin Silva is an Associate Professor and State Extension Specialist in Organic and Sustainable Cropping Systems in the Department of Plant Pathology as well as the Director for the Center for Integrated Agricultural Systems in the College of Agricultural and Life Sciences at UW-Madison. Her research influences the strong organic sector that contributes to Wisconsin's agricultural economy, with Wisconsin second only to California as the state with the greatest number of organic farms. In continued support of these farms and the organic sector within the state, nation, and globally, her research and scholarly contributions continue to be directed in the broad area of the biology and agroecology of organic crop management, with emphases on cover crops, soil health, and genotype/ environment interactions. Dr Silva earned her Ph.D. in Horticulture at Washington State University.

In this episode of Tiny Show and Tell Us, a listener writes in to tell us about being born 3 months premature likely due to their mom having HELLP syndrome, a variant of preeclampsia, and taking part in early trials for surfactants. Then we discuss why horseshoe crab blood is blue and the exciting generation of a one-electron bond between carbon atoms. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Xiong Liu, Director of Data Science and AI at Novartis. Novartis is among the world's leading pharmaceutical companies, pioneering data and advanced analytics in the pursuit of new medicines and patient outcomes. Xiong joins Emerj Editorial Director Matthew DeMello to examine how generative AI and foundation models are transforming R&D, clinical workflows, and research collaboration across the life sciences. The discussion highlights how domain-specific data strategies, improved data quality, and shared benchmarks are accelerating discovery and operationalizing AI for measurable ROI in biopharma. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Mazin Gadir, a regional expert in digital health strategy, Director with Alvarez & Marsal Healthcare and Life Sciences in Dubai, reflects on the Middle East's evolution from early EMR adoption to AI-driven healthcare. From Dubai's innovation playground to Abu Dhabi's depth in research, he explains how rivalry between Gulf states fuels progress and why exporting tested models to Africa and beyond is the new norm. He also questions the myth of leapfrogging, pointing out that fragmentation and lack of research remain barriers. This candid conversation explores regulation, interoperability, and the role of academia in sustaining innovation. www.facesofdigitalhealth.com Newsletter: https://fodh.substack.com/ 00:00 – Introduction: blockchain hype and digital health evolution 01:00 – From EMRs to health information exchanges in the Middle East 03:00 – The impact of COVID-19 on digital transformation 04:30 – Rise of patient empowerment and consumerization of healthcare 05:30 – The missing role of academia and research in the region 07:00 – Comparing Abu Dhabi and Dubai's different innovation models 09:00 – Dubai as a playground for testing, Abu Dhabi for research depth 10:30 – Rivalry across GCC states as a driver of innovation 12:00 – Exporting Gulf digital health models to Africa and beyond 14:00 – Challenges of scaling across Middle Eastern countries 16:00 – Interoperability: current maturity and pilgrim use cases 18:00 – Opportunities and limits of leapfrogging 20:00 – The role of academia and sustainability of innovation www.facesofdigitalhealth.com https://fodh.substack.com/

Life sciences organizations are facing both intense pressure and extraordinary opportunity, according to Mark Sullivan, president of regulated industries at Salesforce. In a conversation with The Top Line’s Chris Hayden, Sullivan said companies too often operate in “survival mode,” focused on defending margins rather than leading innovation. But with the rise of AI and agentic technologies, he said, the industry is poised for a transformation that could reshape how drugs are developed, trials conducted and patient data used — all at greater speed and lower cost. Sullivan emphasized that this new era requires rethinking how companies engage with stakeholders. Instead of distant, one-way interactions, he said, agentic AI enables dynamic, conversational relationships that improve satisfaction and generate actionable insights. Salesforce, he noted, is expanding beyond its CRM roots to help life science enterprises become “agentic” organizations — integrating secure, compliant AI systems across finance, HR and supply chains. With data security and trust at the core, Sullivan called on leaders to look beyond software replacement and pursue true digital transformation for the good of patients and the industry alike.See omnystudio.com/listener for privacy information.

In this 5 in 5 episode, I breaks down five key lessons from Dominic Colenso, actor turned communication coach, on how to present and connect with impact in Pharma, Life Sciences, and Healthcare.Learn how to start with your audience, tell powerful stories, design smarter slides, and lead with emotion to inspire action.Perfect for professionals who want to communicate clearly, confidently, and persuasively.Watch on YouTube: https://youtu.be/ZKZs7FH1yHIListen on Apple Podcast: https://podcasts.apple.com/gb/podcast/hands-on-business-the-h-files-unlocking-growth/id1548129226

Dr. Dan Pardi is the Chief Health Officer at Qualia Life Sciences, where he leads education initiatives focused on advancing healthspan and optimizing peak performance. Qualia Life Sciences develops products rooted in complex systems science, a framework that recognizes the body's natural ability to self-regulate and heal. Their growing product line includes support for brain health, cellular health, NAD+ levels, and most recently, Stem Cells.Dr. Pardi holds a PhD in Cognitive Neuroscience from Leiden University and Stanford. His work is dedicated to translating cutting-edge scientific research into practical tools and programs that help people live longer, healthier, and higher-performing lives. SHOWNOTES:

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today's guest is Mathias Cousin, Managing Director at Deloitte. With extensive experience in R&D transformation and regulated industry data strategy, Mathias joins Emerj Editorial Director Matthew DeMello to unpack what it really takes for enterprise leaders to deliver ROI from AI and data initiatives. Mathias also shares actionable guidance on building effective “string of pearls” use cases, investing in data quality and AI-native talent, and adopting practical change management to embed AI in workflows for measurable gains in efficiency and long-term competitive edge. This episode is sponsored by Deloitte. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

For thousands of years, the rise and fall of empires and the global economy were closely tied to something you might not expect: spices. The spice trade began around 1000 BCE, localized to southeast Asia and the Middle East. But by the beginning of the next millennia, it had rapidly expanded and nations vied to control it. Today it's typically far less work to find and purchase spices you want, but just because they're no longer starting wars that upend nations doesn't mean they're any less important. Because while you might think spices are mostly about making your food taste good, science — and particularly chemistry — is finding they can do a whole lot more.Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Investing in health and science research isn't just about curing diseases. It has huge impacts across society, from creating jobs to driving economic growth to boosting national competitiveness. Study shows that every $ invested in the life sciences industry generates $3 in GDP globally, whereas every job created in the life sciences industry generates five in the global economy. Life sciences are one of the most powerful engines of prosperity, yet many governments still underestimate their economic return.In this episode of The Ripple Effect: Investing in Life Sciences, host Dan Riskin speaks with Patrick Horber, President of Novartis International, and David Gluckman, Vice Chairman of Investment Banking and Global Head of Healthcare at Lazard. Together, they break down the outsized economic impact of life science innovation, from trillions in US bioscience output to China's meteoric rise as a global R&D hub. The conversation delves into the ways governments can support innovation with not just money, but through policy and regulation; plus, some of the best ways that countries can help the sector secure investment, talent, and long-term growth.This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Host: Dan RiskinGuests: Patrick Horber, David Gluckman  Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For the first time in decades, a major innovation in reproductive health is on the horizon. In this episode of StartUp Health NOW, StartUp Health community member Dr. Darlene Walley, CEO of NEXT Life Sciences, joins Unity Stoakes to discuss Plan A™, a long-acting, non-hormonal, fully reversible male contraceptive that could reshape how couples share family planning. Dr. Walley explains how Plan A works as a medical device, the company's global license for Vasalgel®, and the breakthrough results from 100% successful delivery device trials across two continents. With FDA-approved development plans and growing clinical momentum, the company is on track to submit for approval by 2027. Beyond science, this conversation explores a cultural shift: how men are stepping up to share responsibility for contraception and how this innovation could expand access, improve preventive care, and strengthen relationships worldwide. Listen in for a look at the future of men's health, reproductive equity, and one of the most anticipated breakthroughs in medical innovation. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.